Key Points
HYDERABAD: Pharma major Aurobindo Pharma Ltd has posted a nearly 9% rise in consolidated net profit for the quarter ended Sept 30,2024, at Rs 817 crore as compared to Rs 752 crore in the corresponding quarter of last financial year...
This was on an 8% increase in consolidated revenue from operations for Q2FY25 at Rs 7796 crore from Rs 7219 crore in Q2FY24...
Revenues from formulations grew 11.3% to Rs 6640 crore during Q2FY25 from Rs 5968 crore with US market (excluding Puerto Rico) accounting for a 4.3% revenue increase to Rs 3530 crore from Rs 3385 crore and that from European formulations revenues rising 19% to Rs 2105 crore...
In terms of active pharmaceutical ingredients, revenues declined marginally by around 1% to Rs 1156 crore from Rs 1166 crore with revenues from beta-lactam APIs growing 2.5% to Rs 837 crore and that from non beta-lactam APIs falling nearly 9% to Rs 319 crore...
Commenting on the performance, Aurobindo Pharma vice-chairman & managing director K Nithyananda Reddy said: "We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio..
